Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibrosarcoma - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Fibrosarcoma - Pipeline Review, H2 2016', provides an overview of the Fibrosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Fibrosarcoma - The report reviews pipeline therapeutics for Fibrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Fibrosarcoma therapeutics and enlists all their major and minor projects - The report assesses Fibrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Fibrosarcoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Fibrosarcoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibrosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Fibrosarcoma Overview 7 Therapeutics Development 8 Pipeline Products for Fibrosarcoma - Overview 8 Pipeline Products for Fibrosarcoma - Comparative Analysis 9 Fibrosarcoma - Therapeutics under Development by Companies 10 Fibrosarcoma - Therapeutics under Investigation by Universities/Institutes 11 Fibrosarcoma - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Fibrosarcoma - Products under Development by Companies 15 Fibrosarcoma - Products under Investigation by Universities/Institutes 16 Fibrosarcoma - Companies Involved in Therapeutics Development 17 Advanced Proteome Therapeutics Corporation 17 Advenchen Laboratories, LLC 18 Daiichi Sankyo Company, Limited 19 Elsalys Biotech SAS 20 Millennium Pharmaceuticals Inc 21 Novartis AG 22 Rigontec GmbH 23 Sumitomo Dainippon Pharma Co., Ltd. 24 Fibrosarcoma - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 AL-3818 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 APC-103 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Cellular Immunotherapy for Oncology - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 DSR-6434 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 everolimus - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 ImOl-100 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 LK-3 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 MAT-303 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 PLX-7486 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 sapanisertib - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 SEN-461 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 SOM-0777 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Fibrosarcoma - Dormant Projects 62 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for Fibrosarcoma, H2 2016 8 Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Fibrosarcoma - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2016 17 Fibrosarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2016 18 Fibrosarcoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 19 Fibrosarcoma - Pipeline by Elsalys Biotech SAS, H2 2016 20 Fibrosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 21 Fibrosarcoma - Pipeline by Novartis AG, H2 2016 22 Fibrosarcoma - Pipeline by Rigontec GmbH, H2 2016 23 Fibrosarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Fibrosarcoma - Dormant Projects, H2 2016 62
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
